REMARKS

Claims 10-14 are pending in the application. Claims 10-14 have been amended.

- 1. Claims 10-14 have been rejected under 35 USC 112, first paragraph, as not reasonably providing enablement for "solvates" according to the Examiner. In view of the amendment to the claims this rejection is now moot.
- 2. Claims 12 and 13 have been rejected under 35 USC 112, first paragraph, for non-compliance with the enablement requirement with respect to the term "neurological diseases" according to the Examiner. In view of the amendment to the claims this rejection is now moot.
- 3. Claims 13 and 14 have been rejected under 35 USC 112, second paragraph, as being improperly dependent upon canceled claim 1. In view of the amendment to the claims this rejection is now moot.
- 4. Claims 10 and 12-14 have been rejected under 35 USC 102(b) as being anticipated by Himmelsbach et al., U.S. Patent No. 5,519,036. It is the Examiner's position that Himmelsbach teaches the compounds, compositions and methods of use of the compounds of formula (I) where R¹ is cyclopropyl or cyclohexyl; R² is 2-oxo-1-imidazolidinyl-cyclohexanepropanoic acid, i.e.,

$$CO_2H$$

In view of the amendment to Claims 10 and 14 to recite that R^1 represents cylcobutyl or cyclopentyl optionally substituted by C_{1-3} alkyl, this rejection is now moot.

5. Claims 10 and 12-14 have been rejected under 35 USC 102(b) as being anticipated by Himmelsbach et al., WO 99/05194. It is the Examiner's position that Himmelsbach teaches the compounds, compositions, and method of use of the compounds of formula (I) where R¹ is cyclopropyl, R² is 2-oxo-1-imidazolidinyl-cyclohexanepropanoic acid or 2-oxo-1-imidazolidinyl-cyclohexanepropanoic acid methyl ester, i.e.,

In view of the amendment to Claims 10 and 14 to recite that R^1 represents cylcobutyl or cyclopentyl optionally substituted by C_{1-3} alkyl, this rejection is now moot.

Basis for this amendment to Claims 10 and 14 is found in the application at page 5, lines 1-2.

It is respectfully submitted that the present application is in condition for allowance, and a Notice of Allowance is earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

Sonnie L. Deppenbrock
Attorney for Applicant

Registration No. 28,209

Date: Necember 2, 2008

Customer No. 23347 GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-1577 Facsimile: 919-483-7988